A new vaccine aimed at preventing cervical cancer is nearly 100 percent effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer. Results of a nationwide study of the vaccine will be published in the May 10 issue of the New England Journal of Medicine.
But for the next generation of young women, a series of three shots of a new HPV vaccine marketed by Merck under the name Gardasil could make the difference in preventing cervical cancer. The vaccine targets HPV types 16 and 18, which cause about 70 percent of all cases of cervical cancer. It also targets HPV types 6 and 11, which together cause about 90 percent of all cases of genital warts.
AdvertisementResearchers at more than a dozen international medical centers evaluated the efficacy of quadrivalent vaccine targeting HPV types 6, 11, 16, 18 in more than 12,000 women ages 15 to 26 in 13 countries for nearly three years. They found a near 100 percent efficacy rate in prevention of HPV types 16 and 18.
"It's the first vaccine designed specifically to prevent cancer," says Dr. Ault, one of the authors of the study and a key researcher in the development of the vaccine. "The two main things to emphasize are the vaccine efficacy and the safety. These clinical trials have consistent efficacy around 98 percent. And severe reactions to the vaccine appear to be rare."
According to estimates from the Centers for Disease Control and Prevention (CDC) more than 20 million men and women in the US are infected with HPV, and more than six million new infections are reported each year, making it the most common sexually transmitted disease in the nation.
"Nearly all sexually active people are going to get exposed to the virus sometime during their lives," says Dr. Ault. "For most people, HPV causes no complications and goes away on its own. However, in some cases, if left untreated, certain high-risk types of HPV can lead to cervical cancer.
"The goal of the study was to see if we could prevent precancerous cases and we were 98 percent effective. Everyone who gets cancer goes through a pre-cancerous stage," says Ault. "There are about 50 to 60 million pap smears performed each year in the US, and about seven percent are abnormal. We spend about 3 billion dollars each year to find and treat these pre-cancerous stages caused by some type of HPV."
Researchers believe the vaccine will be effective in lowering a girl's lifetime risk of cervical cancer. To that end Merck launched the national "One Less" campaign last year, which encourages females eligible for the vaccine to begin their vaccination series of three shots over six months and to continue seeing their doctor for regular checkups and screenings.
Source: Emory WHSC
PFirst Ever Patch Drug To Treat Parkinsons Symptoms Approved Allergy Alert on Undeclared Peanuts in Mayfield Turtle Tracks Ice Cream M
You May Also Like